DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...
TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...
Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...
3d
Fintel on MSNHC Wainwright & Co. Downgrades Checkpoint Therapeutics (CKPT)Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...
4d
Fintel on MSNLake Street Downgrades Checkpoint Therapeutics (CKPT)Fintel reports that on March 10, 2025, Lake Street downgraded their outlook for Checkpoint Therapeutics (NasdaqCM:CKPT) from ...
The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We ...
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results